BioSpaceOriginal article
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
Phase 2negativeTREM2 stabilizerNegative
AI Analysis
Summary
Novartis halted its TREM2-targeting ALS program after the drug failed to demonstrate efficacy in a Phase 2 trial of early-stage patients. This marks the company's fourth trial setback in one month, including two late-stage failures and a CAR T cell program pause due to patient deaths.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Failed to show efficacy in Phase 2 trial of patients with early-stage ALS
Importance:7/10
Sentiment:
-0.90
Phase 2 failureALSTREM2trial stoppageefficacy failureCAR T cell safety concerns
Related Companies
Read the original article
Published by BioSpace on September 16, 2026 1:41 PM